InterCure Ltd. (NASDAQ:INCR) Sees Large Drop in Short Interest

InterCure Ltd. (NASDAQ:INCRGet Free Report) was the target of a large drop in short interest in the month of December. As of December 31st, there was short interest totaling 6,703 shares, a drop of 50.6% from the December 15th total of 13,558 shares. Based on an average daily trading volume, of 190,443 shares, the short-interest ratio is presently 0.0 days. Based on an average daily trading volume, of 190,443 shares, the short-interest ratio is presently 0.0 days.

InterCure Stock Up 1.0%

Shares of INCR traded up $0.01 during mid-day trading on Friday, reaching $0.96. 31,779 shares of the company were exchanged, compared to its average volume of 171,085. InterCure has a 52 week low of $0.68 and a 52 week high of $1.78. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.85 and a quick ratio of 1.09. The business has a 50 day simple moving average of $1.22 and a two-hundred day simple moving average of $1.43.

InterCure (NASDAQ:INCRGet Free Report) last announced its earnings results on Wednesday, October 8th. The company reported ($0.02) EPS for the quarter. The company had revenue of $19.25 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of InterCure in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on INCR

About InterCure

(Get Free Report)

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.

Featured Stories

Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.